Himmelfarb Health Sciences Library, The George Washington University

Health Sciences Research Commons
Emergency Medicine Faculty Publications

Emergency Medicine

12-15-2012

Current opinion on nanotoxicology
Ali Pourmand
George Washington University

Mohammad Abdollahi
University of Toronto

Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/smhs_emerg_facpubs
Part of the Emergency Medicine Commons
Recommended Citation
Pourmand, A. & Abdollahi, M. (2012). Current opinion on nanotoxicology, DARU Journal of Pharmaceutical Sciences, 20:95.

This Editorial is brought to you for free and open access by the Emergency Medicine at Health Sciences Research Commons. It has been accepted for
inclusion in Emergency Medicine Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information,
please contact hsrc@gwu.edu.

Pourmand and Abdollahi DARU Journal of Pharmaceutical Sciences 2012, 20:95
http://www.darujps.com/content/20/1/95

EDITORIAL

Open Access

Current Opinion on Nanotoxicology
Ali Pourmand1 and Mohammad Abdollahi2*
Abstract
Nanotechnology is one of the premiere technologies available today, having expanded both as field of scientific
study and in the public consciousness. Despite this growth, the drawbacks, limitations and potential safety
hazards associated with the incorporation of nanotechnology into existing industries are still being learned. The
noticeable point is that there is no enough data available yet to analyze global use of nanotechnology from a
meta-perspective. Three challenges can be defined in light of nanotoxicology. One, materials that might prove to
be significantly toxic must be identified. Two, a system for the categorization of NP materials must be codified and
made available to toxicologists. Third, a better understanding of nanoparticles biological interactions must be
obtained, in order to make the best use of the first two goals. For all three, it must be remembered that research
standards need to be developed for the gathering of data on the nanoscale, as that level is where the NPs and the
patient’s biosystems will be interacting.
As requiring toxicologists to become nanotechnology experts would not be feasible, to properly incorporate the
care of nanotoxicity into the existing medical framework, a range of experts across multiple fields of study must
work in close synchronization. The focus needs to be on mechanism-driven research to ensure a solid scientific
foundation for the assessment of NP and their role in healthcare.
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Nanotechnology is one of the premiere technologies
available today, having expanded both as field of scientific study and in the public consciousness. Despite this
growth, the drawbacks, limitations and potential safety
hazards associated with the incorporation of nanotechnology into existing industries are still being learned.
The noticeable point is that there is no enough data
available yet to analyze global use of nanotechnology
from a meta-perspective.
The conventional definition of a nanoparticle (NP) is a
material or materials with two or three dimensions, between 1 and 100 nm and possessing strange properties
related to the size, shape or chemical composition of the
material. The term nanotechnology can be defined as
“the manipulation, measurement, precision, modeling,
or manufacture of sub-100 nanometer scale matter” [1].
Today, over 800 consumer products are estimated to incorporate nanoparticles [2,3].
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Of particular interest to the medical field is the potential advantage of nanotechnology in both diagnostic and
therapeutic approaches. The ability to operate at the cellular or intercellular level could lead to dramatic leaps in
the patient care. As of this writing, NPs are being developed to meet a variety of needs, however very few NPs
have made it out of the testing phase. Over the last five
years, production of NPs has increased five-fold. The
current approximation is that more than 580 companies
over 30 countries manage and produce some 1,317 NPbased projects, from textiles to wound dressings [2].
Some scientists have speculated that nanotechnology is
growing because of recognition that a targeted, cell-bycell approach brings greater benefits than an undifferentiated approach [4].
However, there are significant concerns associated
with the use of NPs. The primary concerns are with how
easily NPs can penetrate cell membranes. When compared to non-NPs, NPs can more easily pass into various
biological structures, creating a potentially toxic effect.
On a macro-scale, the increasing presence of NPs on an
environmental level may also have negative consequences, however, the current knowledge is not enough
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to reach a convincing consensus. For instance, NPs
designed to act as chemical catalysts for particular
chemical reactions, might, due to their physical structure
have undesirable effects in the human body. In one particular case, the respiratory system was harmed by NPs
[5-7]. With these concerns, a growing body of professionals is seeking development of toxicology screenings
that specifically target NPs [8,9].
Categorizations of NPs tend to fall into carbon-based
NPs, i.e. fullerenes and carbon nanotubes, and inorganic
NPs, ones based on the metal oxides (iron oxide, cerium
oxide, titanium dioxide, silicon dioxide), metals (gold
and silver), and semiconductor NPs or so-called
quantum dots [10]. All of the above could have hazardous effects but a comprehensive analysis of each
NP class has yet to occur. NPs production can be
divided into four major steps such as gas-phase, vapor
deposition, colloidal and attrition, and each step could
cause toxicity by gastrointestinal, pulmonary or skin
exposure [11].
The danger that NPs pose is related to their very nature. Due to their miniscule size, NPs can collect nearly
anywhere in a biological system. Whether a person
absorbs NPs in the process of taking nano-based drugs,
through topical skin applications or by inadvertent inhalation of NPs makes no difference when considering the
potential harm due to nanotoxicity. The toxic effects
might be compounded in cases involving NPs deliberately manufactured for use in industry as those NPs
might promote harmful chemical reactions once in
the body.
Specifically, the small scale of NPs allow them to bypass the usual barriers to cell uptake and can enter sensitive tissues such as bone marrow, lymph nodes, spleen
and the heart by way of blood circulation or lymphatic
channels [12]. Of course, such entry depends on the
chemical makeup of the NPs. When endocytosis occurs
with a foreign matter such as NPs, there is a risk of inflammatory activity, sometimes pro-oxidant, sometimes
antioxidant [12,13]. There is evidence that the body produces an oxidative stress response, which, when coupled
with mitochondrial distribution may result in some disadvantages that remain to be clarified. NPs at the scale
of biological macromolecules could easily hybridize, as
several features of certain NPs give them advantaged
when compared to biological molecules. For instance,
NPs introduced to the body through sunscreen pass
through the skin due to their small size, avoid
neutralization by the immune system due to their composition, and their tendency to produce free radicals
have concerned experts who fear that if sunscreen NPs
prove toxic, they might be impossible to flush out of the
body [14]. Other dangers include protein degradation
brought on by the large surface area of NPs compared to
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the small surface area of larger particles [15], which can
be observed in various processes with taking DNA
macromolecules and using them to solubilize highly
hydrophobic single-walled carbon nanotubes [16]. These
carbon nanotubes can induce DNA strand breaks due to
a greater amount of intrusion into the cell nuclei, or
even create micronuclei [17].
Dosing also becomes a greatly complicated affair on
the nanoscale, with the potential benefits being weighted
against the danger of exposing a compromised organism
to NPs [12]. There are many aspects of medicinal NPs
use that must be defined, such as the effects of the NP’s
size, shape and chemical composition. Furthermore,
questions exist as to how long a NP dose remains in the
body. Are they eventually flushed out of a particular cell?
If so, how long does that process take, from start to finish? When the body absorbs NPs for therapeutic purposes, do they simple provide an enhanced version of
the effects seen in large particles or are the NPs creating
entirely new effects, with the added danger of unforeseen side effects [18,19]? And what of “antigenic challenges”? Could engineered NPs diminish the function of
the immunological apparatus? Can the effects of NPs be
predicted with any type of accuracy? Or precise measurements taken at that scale? And in the case of adverse effects, the small scale of NPs means NPs could
affect organs very distant from their point of entry. Even
the use of targeting ligands applied to the surface of NPs
to ensure delivery of a nanodevice to a specific anatomical location or cell type. One case to focus on is the use
of flexible hydrophilic polymers, specifically those incorporating polyethylene glycol (PEG), which limit
opsonization of the NPs and give them opportunity to
remain in circulation for longer time periods [20]. Due
to the fact that the NPs remained circulating, they
reached various additional structures and, depending on
the type of NP, build up in those new structures. An example comes from the early days of research of the biodistribution of model polystyrene NPs, which were
coated with poloxamers. These elements attach to particle surfaces via their hydrophobic areas, and the hydrophilic sections come through into the aqueous medium
and these particles found to concentrate to significant
extent in the bone marrow, specifically the sinusoidal
bone marrow endothelium [21]. Other areas of accumulation were the brain, gut, spleen, and lymph nodes
[22,23]. Obviously the potential dangers of having foreign NPs building up in the body cannot be ignored.
Thus the discipline of nanotoxicology, which seeks to
define and demarcate the effects caused by artificial NPs
and establish the relationship between NPs and toxicity.
Up until the present day, those studying the phenomenon of nanotoxicology focused on NPs made of conventional material, TiO2, ZnO and Ag, for example, with
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the occasional special material such as carbon nanotubes. With the recent advances in nanotechnology however, that approach will no longer allow toxicologists to
stay on top of the development and potential hazards
posed by the increasingly sophisticated NPs now in production, build using multicomponent materials, hybrid
materials that sit on the line between organic and inorganic, and materials designed to change their behavior
based on either the environment or a received signal
[24]. As such complicated NPs became more and more
widely accepted, there has been a greater recognition of
the lack of toxicological knowledge about these new
substances [25].
Therefore, three challenges can be defined in light of
this new information. One, materials that might prove to
be significantly toxic must be identified. Two, a system
for the categorization of NP materials must be codified
and made available to toxicologists. Third, a better
understanding of NPs’ biological interactions must be
obtained, in order to make the best use of the first two
goals. For all three, it must be remembered that research
standards need to be developed for the gathering of data
on the nanoscale, as that level is where the NPs and the
patient’s biosystems will be interacting.
As requiring toxicologists to become nanotechnology
experts would not be feasible, to properly incorporate
the care of nanotoxicity into the existing medical framework, a range of experts across multiple fields of study
must work in close synchronization. The focus needs to
be on mechanism-driven research to ensure a solid scientific foundation for the assessment of NP and their
role in healthcare.
Competing interests
The authors have no commercial associations or sources of support that
might pose a competing interest.

4.

5.

6.
7.

8.

9.
10.
11.

12.

13.

14.

15.

16.

17.

18.

19.
20.

Authors’ contributions
Both authors have made substantive equal contributions to the paper and
read and approved the final manuscript.
Author details
1
Department of Emergency Medicine, George Washington University Medical
Center, 2150 Pennsylvania, Ave NW, Suite 2B, Washington, DC 20037, USA.
2
Department of Toxicology and Pharmacology, Faculty of Pharmacy and
Pharmaceutical Sciences Research Center, Tehran University of Medical
Sciences, Tehran 1417614411, Iran.
Received: 22 November 2012 Accepted: 22 November 2012
Published: 15 December 2012

21.

22.
23.

24.
25.

References
1. Meyer M, Persson O, Power Y: Mapping excellence in nanotechnologies:
Preparatory study (Nanotechnology expert group and Eurotech data).
European Commission: Report to the European Commission; 2001.
2. The Project on Emerging Nanotechnologies Consumer Products Inventory.
http://www.nanotechproject.org/inventories/consumer/, accessed Nov.
2012.
3. Marquis BJ, Love SA, Braun KL, Haynes CL: Analytical methods to assess
nanoparticle toxicity. Analyst 2009, 134:425–439.

Page 3 of 3

Pourmand A, Pourmand MR, Wang J, Shesser R: Application of
nanomedicine in emergency medicine; point-of-care testing and drug
delivery in twenty - first century. DARU 2012, 20(26):1–3.
Tran CL, Buchanan D, Cullen RT, Searl A, Jones AD, Donaldson K: Inhalation
of poorly soluble particles. II. Influence of particle surface area on
inflammation and clearance. Inhal Toxicol 2000, 12:1113–1126.
Donaldson K, Tran CL: Inflammation caused by particles and fibres. Inhal
Toxicol 2002, 14:5–27.
Donaldson K, Aitken R, Tran L, Stone V, Duffin R, Forrest G, Alexander A:
Carbon nanotubes: a review of their properties in relation to pulmonary
toxicology and workplace safety. Toxicol Sci 2006, 92:5–22.
Chaudhry Q, Blackburn J, Floyd P: Final Report: A scoping study to identify
gaps in environmental regulation for the products and applications of
nanotechnologies. http://www.defra.gov.uk/science/project_data/
DocumentLibrary/CB01075/CB01075_3373_FRP.doc.
Nordan MM, Holman MW: A prudent approach to nanotechnology
environmental, health and safety risks. Ind Biotechnol 2005, 1:146–149.
Eghbalnia M: Electrochemical and Raman investigation of pyrite and
chalcopyrite oxidation. https://circle.ubc.ca/handle/2429/41999.
Aitken RJ, Creely KS, Tran CL: Nanoparticles: An occupational hygiene review,
Volume 274 of Research report. http://www.hse.gov.uk/research/rrpdf/rr274.
pdf.
Oberdorster G, Oberdorster E, Oberdorster J: Nanotoxicology: an emerging
discipline evolving from studies of ultrafine particles. Environ Health
Perspect 2005, 113:823–839.
Shafiee H, Mohammadi H, Rezayat SM, Hosseini A, Baeeri M, Hassani S,
Mohammadirad A, Bayrami Z, Abdollahi M: Prevention of malathioninduced depletion of cardiac cells mitochondrial energy and free radical
damage by a magnetic magnesium-carrying nanoparticle. Toxicol Mech
Methods 2010, 20:538–543.
Newman M, Stotland M, Ellis J: The safety of nanosized particles in
titanium dioxide and zinc oxideebased sunscreens. J Am Acad Dermatol
2009, 61:685–692.
Borm PJ, Kreyling W: Toxicological hazards of inhaled nanoparticlespotential implications for drug delivery. J Nanosci Nanotechnol 2004,
4:521–531.
Yamamoto Y, Fujigaya T, Niidome Y, Nakashima N: Fundamental properties
of oligo double-stranded DNA/single-walled carbon nanotube
nanobiohybrids. Nanoscale 2010, 2:1767–1772.
Cveticanin J, Joksic G, Leskovac A, Petrovic S, Sobot AV, Neskovic O: Using
carbon nanotubes to induce micronuclei and double strand breaks of
the DNA in human cells. Nanotechnology 2010, 21:015102.
Oberdorster G, Utell MJ: Ultrafine particles in the urban air: to the
respiratory tract-and beyond? Environ Health Perspect 2002,
110:A440–A441.
De Jong WH, Borm PJ: Drug delivery and nanoparticles: applications and
hazards. Int J Nanomedicine 2008, 3:133–149.
Stolnik S, Illum L, Davis SS: Long circulating microparticulate drug carriers.
Adv Drug Deliv Rev 1995, 16:195–214.
Porter CJ, Moghimi SM, Illum L, Davis SS: The polyoxyethylene/
polyoxypropylene block copolymer-407 selectively redirects
intravenously injected microspheres to sinusoidal endothelial cells of
rabbit bone marrow. FEBS Lett 1992, 305:63–66.
Kreuter J: Nanoparticulate systems for brain delivery of drugs. Adv Drug
Deliv Rev 2001, 47:65–81.
Lind K, Kresse M, Debus NP, Müller RH: A novel formulation for
superparamagnetic iron oxide (SPIO) particle enhancing MR
lymphography: comparison of physicochemical properties and the
in vivo behavior. J Drug Target 2002, 10:221–230.
Subramanian V, Youtie J, Porter AL, Shapira P: Is there a shift to “active”
nanostructures? J Nanopart Res 2010, 12:1–10.
Song Y, Li X, Du X: Exposure to nanoparticles is related to pleural
effusion, pulmonary fibrosis and granuloma. Eur Respir J 2009, 34:559–567.

doi:10.1186/2008-2231-20-95
Cite this article as: Pourmand and Abdollahi: Current Opinion on
Nanotoxicology. DARU Journal of Pharmaceutical Sciences 2012 20:95.

